UY40256A - Formas de sales y cristales de un inhibidor del receptor del factor de crecimiento epidérmico - Google Patents

Formas de sales y cristales de un inhibidor del receptor del factor de crecimiento epidérmico

Info

Publication number
UY40256A
UY40256A UY0001040256A UY40256A UY40256A UY 40256 A UY40256 A UY 40256A UY 0001040256 A UY0001040256 A UY 0001040256A UY 40256 A UY40256 A UY 40256A UY 40256 A UY40256 A UY 40256A
Authority
UY
Uruguay
Prior art keywords
growth factor
factor receptor
epidermal growth
salt
crystal forms
Prior art date
Application number
UY0001040256A
Other languages
English (en)
Spanish (es)
Inventor
Tian Xie
Eric Gruff
Shanming Kuang
Anjali Pandey
Harsh Shah
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of UY40256A publication Critical patent/UY40256A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY0001040256A 2022-05-04 2023-05-04 Formas de sales y cristales de un inhibidor del receptor del factor de crecimiento epidérmico UY40256A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263338371P 2022-05-04 2022-05-04

Publications (1)

Publication Number Publication Date
UY40256A true UY40256A (es) 2023-11-15

Family

ID=86688767

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040256A UY40256A (es) 2022-05-04 2023-05-04 Formas de sales y cristales de un inhibidor del receptor del factor de crecimiento epidérmico

Country Status (12)

Country Link
US (1) US20250282761A1 (cg-RX-API-DMAC7.html)
EP (1) EP4519254A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025517634A (cg-RX-API-DMAC7.html)
KR (1) KR20250012078A (cg-RX-API-DMAC7.html)
CN (1) CN119923392A (cg-RX-API-DMAC7.html)
AU (1) AU2023265064A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251624A1 (cg-RX-API-DMAC7.html)
IL (1) IL316663A (cg-RX-API-DMAC7.html)
MX (1) MX2024013485A (cg-RX-API-DMAC7.html)
TW (1) TW202409016A (cg-RX-API-DMAC7.html)
UY (1) UY40256A (cg-RX-API-DMAC7.html)
WO (1) WO2023215431A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202432143A (zh) * 2022-11-01 2024-08-16 美商纜圖藥品公司 用於治療癌症之egfr抑制劑

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493419A (zh) * 2020-03-18 2021-10-12 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
CN113493420B (zh) * 2020-03-18 2025-04-25 南京迈晟科技有限责任公司 Egfr酪氨酸激酶抑制剂及其用途
EP4237418B1 (en) * 2020-10-30 2026-02-11 Blueprint Medicines Corporation Pyrimidine compounds, compositions, and medicinal applications thereof
EP4237088A1 (en) * 2020-10-30 2023-09-06 Blueprint Medicines Corporation Pyrimidine compounds, compositions, and medicinal applications thereof

Also Published As

Publication number Publication date
JP2025517634A (ja) 2025-06-10
AU2023265064A1 (en) 2024-11-14
TW202409016A (zh) 2024-03-01
EP4519254A1 (en) 2025-03-12
MX2024013485A (es) 2024-12-06
KR20250012078A (ko) 2025-01-23
WO2023215431A1 (en) 2023-11-09
US20250282761A1 (en) 2025-09-11
CN119923392A (zh) 2025-05-02
IL316663A (en) 2024-12-01
CA3251624A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
CO2024012743A2 (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
CO2022008091A2 (es) Inhibidores de kras g12c
PY1996328A (es) Compuestos de azalactam como inhibidores de hpk1
PE20250667A1 (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2
UY38553A (es) Inhibidores de cdk2
CO2023001579A2 (es) Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este
UY38144A (es) Inhibidores de la señalización mediada por tirosina cinasa
UY39517A (es) Inhibidores de la btk
CO2024012423A2 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
MX2020007947A (es) Inhibidores de erbb/btk.
AR047917A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
CO2022018806A2 (es) Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblastos
CL2023000712A1 (es) Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos
MX2024009161A (es) Compuestos de pirrolidina.
CL2024003274A1 (es) Métodos para producir compuestos halogenados
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
CO2024011857A2 (es) Compuestos de uracilo n3-sustituidos como inhibidores de trpa1
CL2025002615A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
CU20210044A7 (es) Pirazoles como moduladores de hemoglobina
MX2021004917A (es) Sales cristalinas de un inhibidor de calicreina plasmatica.
ECSP23091202A (es) Moduladores de trex1
CO2024000832A2 (es) Inhibidores de transglutaminasas

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20240513